NOVO.B.DK

449.4

-3.3%↓

COLO.B.DK

722.4

+4.03%↑

ZEAL.DK

446.6

-4.25%↓

HLUNB.DK

31.3

-2.13%↓

AMBUB.DK

111.6

-2.87%↓

NOVO.B.DK

449.4

-3.3%↓

COLO.B.DK

722.4

+4.03%↑

ZEAL.DK

446.6

-4.25%↓

HLUNB.DK

31.3

-2.13%↓

AMBUB.DK

111.6

-2.87%↓

NOVO.B.DK

449.4

-3.3%↓

COLO.B.DK

722.4

+4.03%↑

ZEAL.DK

446.6

-4.25%↓

HLUNB.DK

31.3

-2.13%↓

AMBUB.DK

111.6

-2.87%↓

NOVO.B.DK

449.4

-3.3%↓

COLO.B.DK

722.4

+4.03%↑

ZEAL.DK

446.6

-4.25%↓

HLUNB.DK

31.3

-2.13%↓

AMBUB.DK

111.6

-2.87%↓

NOVO.B.DK

449.4

-3.3%↓

COLO.B.DK

722.4

+4.03%↑

ZEAL.DK

446.6

-4.25%↓

HLUNB.DK

31.3

-2.13%↓

AMBUB.DK

111.6

-2.87%↓

Search

Genmab A-S

Open

1,300 1.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1272

Max

1304.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.1B

3.8B

Verkäufe

901M

6.4B

KGV

Branchendurchschnitt

11.038

63.778

EPS

60.121

Gewinnspanne

59.696

Angestellte

2,682

EBITDA

-297M

1.8B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-1.49% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.2B

85B

Vorheriger Eröffnungskurs

1298.44

Vorheriger Schlusskurs

1300

Genmab A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. März 2025, 15:16 UTC

Wichtige Markttreiber

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10. Dez. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer-Vergleich

Kursveränderung

Genmab A-S Prognose

Kursziel

By TipRanks

-1.49% Nachteil

12-Monats-Prognose

Durchschnitt 2,493.35 DKK  -1.49%

Hoch 3,320 DKK

Tief 308.417 DKK

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Genmab A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

3

Buy

2

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.